

European Good Manufacturing Practices in Smart textiles and new ways of production

Nanostructured textiles to promote skin repair in severe burn injuries

Pilar Sepúlveda, PhD / Òscar Calvo

Instituto de Investigación Sanitaria - IIS La Fe / AITEX

SUMMARY

1. GMP STATE-OF-THE ART: TEXTILE RE-INDUSTRIALIZATION IN THE VALENCIAN REGION AND SOME SUCCESSFUL CASES.


2. ELECTROSPINNING TECHNOLOGY AND PRODUCTION OF BIO-RESPONSIVE ELECTROSPUN MATS

3. RESULTS COMING FROM PRE-CLINICAL TRIALS.

4. CLOSING REMARKS AND NEXT STEPS.

1. GMP STATE-OF-THE ART: TEXTILE RE-INDUSTRIALIZATION IN THE VALENCIAN REGION AND SOME SUCCESSFUL CASES

Situation of the Spanish and Valencian textile industry last 10 years:




Some lacks in terms of:

- Technification of processes and products
- Re-industrialization needs
- 'Traditional' production of 'traditional' textile products (e.g. nonwovens).

Some **funding instruments** are available for national/Valencian textile companies, in order **to improve machinery**, to promote **diversification** of the production and **to reduce lacks in terms of technology level**: REINDUS -national- and CREATEC -Valencia- programmes (co-funded by ERDF EU funds) or the Industrial Modernization Plan -Valencia-.

1. GMP STATE-OF-THE ART: TEXTILE RE-INDUSTRIALIZATION IN THE VALENCIAN REGION AND SOME SUCCESSFUL CASES

Some companies and entities are doing **R&D**, manufacturing and investing on **new technologies** and **new ways of production**:



Clean technologies for textile finishing (JEANOLOGIA, S.L.)



FUN2GARMENT project - New functional and sustainable finishings for fabrics and garments (AITEK)



Development of electrospinning technology (BIOINICIA, S.L.)

STENT-NET project - Development of drug eluting stents using biocompatible nanofiber meshes obtained by electrospinning (AITEK/IIS La Fe)

Oil-enriched new wound dressings for treatment of chronic ulcers and burn skin injuries (AITEK/Solutex/IIS La Fe)




1. GMP STATE-OF-THE ART: TEXTILE RE-INDUSTRIALIZATION IN THE VALENCIAN REGION AND SOME SUCCESSFUL CASES

They are also developing '**classical**' smart-textiles, wearables, printed electronics and promoting the concept '**Industry 4.0**':



SPORT@FUTURE project - New textile and footwear solutions to improve safety, protection, comfort, efficiency and health of the sportive people (partnership: 7 companies)



INSTINTO II project - Smart system based on sensors and actuators integrated into textiles for the purposes of preventing, detecting and protecting against a fall by an elderly wearer (AITEEX)

SCREENTEX II - Printed electronics on flexible substrates (AITEEX)

DIGITALIZA-T project: Industry 4.0 Textile sector (AITEEX)



iTEX4HOTEL - Implantation of RFID technology in textile items for the hotel industry (RESUINSA EXPERIENCES S.L.)




2. ELECTROSPINNING TECHNOLOGY AND PRODUCTION OF BIO-RESPONSIVE ELECTROSPUN MATS

Electrospinning (ES) is a widely used technology to develop **nanofibers and meshes**:

- **Electrospinning** is a fiber production method which uses electric force to draw charged threads of polymer solutions up to nanometrical fibers
- The process does not require the use of coagulation chemistry or high temperatures to produce solid threads from solution.
- This makes the process particularly suited to the production of fibers using large and complex molecules; this method ensures that no solvent can be carried over into the final product.



2. ELECTROSPINNING TECHNOLOGY AND PRODUCTION OF BIO-RESPONSIVE ELECTROSPUN MATS

Different electrospinning devices are available in the market: from easy-to-operate needle-based small devices (e.g. **biomaterials**) to wide formats (production of **industrial goods**: **filtration or acoustic materials, membranes...**).



Polymers for bio-responsive applications and biomedicine must be selected from '**medical grades**'. Here we focus on the treatment of severe burn injuries using electrospun mats (monoaxial) of **bio-compatible poly(D,L-lactide-co-glycolide) (DLPLG)**.

2. ELECTROSPINNING TECHNOLOGY AND PRODUCTION OF BIO-RESPONSIVE ELECTROSPUN MATS



Drug delivery systems

- Nanofibrous membranes are considered as a potential drug carrier, incorporated with drug component can be patched on a wound



Wound dressing

- Electrospun polymer nanofibers are treated as tissue scaffolds which enhance cell growth and proliferation

- Electrospinning technology allows generation of biomaterials with tailor-made thickness and dimensions.
- **Nanofiber webs or mats have a specific area and porosity** controlled by altering the weight and density of fibers by surface unit allowing the adaptation of scaffolds to a particular **tissue engineering application**.

3. RESULTS COMING FROM PRE-CLINICAL TRIALS.

Options for treating severe burn injuries:

- If burn area is **< 50% of total body area**





Best option are AUTOLOGOUS SKIN GRAFTS

- If burn area is **> 50% of total body area**




Unique option is AUTOLOGOUS *ex vivo* EXPANDED DERMAL EQUIVALENT



Current dermal equivalents:

A healthy skin biopsy is taken from the patient and expanded *ex vivo* in a GMP cell culture room to obtain artificial skin from the same patient that will be transplanted as a definitive cover



Definitive coverage
Economic
Good results

Preparation time
Handling
Sensitive to infection
Irregular performance

3. RESULTS COMING FROM PRE-CLINICAL TRIALS.


The main objective of the nanostructured textiles -scaffolds- is to improve the quality of dermal equivalents and to increase their viability and engraftment.

Electrospun scaffolds must fulfill the following requirements:

- Do not cause cell death or be toxic or teratogenic.
- To promote cell adhesion and proliferation.
- To allow homogeneous and continuous cell growth.
- To be biodegradable and biocompatible.
- Do not induce chronic inflammation
- Be sterilizable and easy to handle.

The product generated in this project consists of a electrospun scaffold combined with a dermal equivalent made of fibroblasts and keratinocytes:


- *It provides improved handling of dermal equivalent (DE)*
- *It improves engraftment of DE.*
- *It can be functionalized with growth factors, antibiotics or other active principles.*




3. RESULTS COMING FROM PRE-CLINICAL TRIALS.

Testing. In vitro cellular assays and in-vivo (animal, mice) models:

In vitro cellular assays:



Electrospun poly(hydroxybutyrate) scaffolds promote engraftment of human skin equivalents via macrophage M2 polarization and angiogenesis

Delia Castellano^{1,2†}, Ana Sanchis^{1†}, María Blanes³, M^a. Dolores Pérez del Caz¹, Amparo Ruiz-Sauri⁴, Marina Piquer-Gil^{1,2}, Beatriz Pelacho⁵, Bruno Marco³, Nahuel Garcia^{1,2}, Imelda Ontoria-Oviedo^{1,2}, Vicente Cambra³, Felipe Prosper⁵ and Pilar Sepúlveda^{1,2*} 



¹Instituto de Investigación Sanitaria la Fe, Regenerative Medicine and Heart Transplantation Unit, Valencia, Spain

²Joint Unit for Cardiovascular Repair Instituto de Investigación Sanitaria La Fe-Centro de Investigación Príncipe Felipe, Valencia, Spain

³Instituto Tecnológico Textil Aitex, Alcoy, Spain

⁴Departamento de Patología, Facultad de Medicina, Universidad de Valencia, Valencia, Spain

⁵Laboratory of Cell Therapy, Foundation for Applied Medical Research and Clínica Universidad de Navarra, University of Navarra, Pamplona, Spain




3. RESULTS COMING FROM PRE-CLINICAL TRIALS.

In vitro cellular assays and **in-vivo** mouse models:

In vivo NOD/SCID mice:






4. CLOSING REMARKS AND NEXT STEPS.

- Biomaterials tested are biocompatible in terms of controlled inflammation and cell growth
- Nanofibers **integrate into fibrin matrix** and are **permeable to nutrients and cells**.
- New dermal equivalents with nanofibers are **optimal for clinical handling**.
- New dermal equivalents have **angiogenic capacity** (promotes **formation of new blood vessels**).
- They **improve scar quality, less tension, smooth surface**.
- **They could be improved by adding drugs or growing factors**.

4. CLOSING REMARKS AND NEXT STEPS.



For further information please contact:

Dr. Pilar Sepúlveda, PhD

(pilar.sepulveda.sanchis@gmail.com)

Dr. María Blanes (mblanes@aitex.es)

Mr. Bruno Marco (bmarco@aitex.es)

Mr. Oscar Calvo (ocalvo@aitex.es)

**THANK YOU FOR YOUR
ATTENTION!!!**

<http://www.interregeurope.eu/reset>